Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
4.900
-1.840 (-27.30%)
At close: Dec 5, 2025, 4:00 PM EST
5.10
+0.20 (4.08%)
After-hours: Dec 5, 2025, 6:45 PM EST
Company Description
Exicure, Inc. does not have significant operations.
Previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets.
Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.
Exicure, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Andy Yoo |
Contact Details
Address: 400 Seaport Court, Suite 102 Redwood City, California 94063 United States | |
| Phone | 847 673 1700 |
| Website | exicuretx.com |
Stock Details
| Ticker Symbol | XCUR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001698530 |
| CUSIP Number | 30205M101 |
| ISIN Number | US30205M3097 |
| Employer ID | 81-5333008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Andy Yoo | Chief Executive Officer and Director |
| Seung Ik Baik | Chief Financial Officer, Secretary and Director |
| Dr. Josephine Cardarelli Ph.D. | President and Chief Scientific Officer |
| Joshua Miller | Chief Accounting Officer |
| Dr. Devki Sukhtankar Ph.D. | Head of Preclinical Research and Translational Medicine |
| Dr. Niña Caculitan Ph.D. | Head of Clinical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 17, 2025 | 8-K | Current Report |
| Nov 10, 2025 | 8-K | Current Report |
| Nov 7, 2025 | 10-Q | Quarterly Report |
| Nov 7, 2025 | 8-K | Current Report |
| Sep 23, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 22, 2025 | SCHEDULE 13D/A | Filing |
| Sep 9, 2025 | 8-K | Current Report |
| Aug 8, 2025 | 10-Q | Quarterly Report |
| Aug 8, 2025 | 8-K | Current Report |
| Aug 4, 2025 | 8-K | Current Report |